Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 8/20 | 0.42 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.40 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.33 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.33 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.33 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1872305 | 0.89 | GPBAR1 (0.45) | ABL1GPBAR1DPP4GRM5 | |
| SCHEMBL1873065 | 0.82 | DPP4 (0.37) | DPP4NISCHGRM5 | |
| SCHEMBL1868986 | 0.81 | GPBAR1 (0.45) | GPBAR1DPP4 | |
| SCHEMBL12098356 | 0.80 | GPBAR1 (0.43) | GPBAR1GRM5 | |
| SCHEMBL1875628 | 0.79 | MEN1 (0.37) | DPP4MEN1KMT2A | |
| SCHEMBL1872299 | 0.78 | CYP1A2 (0.43) | ABL1 | |
| SCHEMBL12097299 | 0.77 | LOXL2 (0.45) | ABL1GPBAR1DPP4NISCHPDE10A | |
| SCHEMBL1872166 | 0.76 | CD274 (0.35) | DPP4 | |
| SCHEMBL1873973 | 0.75 | DPP4 (0.43) | DPP4PDE2APDE10A | |
| SCHEMBL1875898 | 0.75 | GPBAR1 (0.41) | ABL1GPBAR1AGPAT2NISCHKCNQ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385022-B2 | 3-amino-pyridines as GPBAR1 agonists | HOFFMANN-LA ROCHE INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20150152058-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | HOFFMANN-LA ROCHE INC. | 2015-06-04 | — | — | US | disclosed |
| EP-2681194-B1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | HOFFMANN LA ROCHE (CH) | 2015-04-15 | — | — | EP | disclosed |
| US-8987307-B2 | 3-amino-pyridines as GPBAR1 agonists | HOFFMANN-LA ROCHE INC. (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2681194-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-8404708-B2 | Dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120232051-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | HOFFMANN-LA ROCHE INC. | 2012-09-13 | — | — | US | disclosed |
| WO-2012117000-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-07 | — | — | WO | disclosed |
| US-20110178055-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | HOFFMANN TORSTEN | 2011-07-21 | — | — | US | disclosed |
| US-7939533-B2 | Dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | disclosed |
| CN-1852712-B | Dual NK1/NK3 antagonists for treating schizophrenia | HOFFMANN LA ROCHE | 2010-06-09 | — | — | CN | disclosed |
| US-20090137806-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | HOFFMANN TORSTEN | 2009-05-28 | — | — | US | disclosed |
| CN-1852712-A | Dual NK1/NK3 antagonists for treating schizophrenia | HOFFMANN LA ROCHE (CH) | 2006-10-25 | — | — | CN | disclosed |
| US-20050090533-A1 | Dual NK1/NK3 receptor antagonists | F. HOFMANN-LA ROCHE AG (CH) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385022-B2 | 3-amino-pyridines as GPBAR1 agonists | GPBAR1, ADRA1B, GPR119 | ABL1 1707/4885GPBAR1 1/4885AGPAT2 484/4885 |
| US-20120232051-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | GPBAR1, ADRA1B, GPR119 | ABL1 1707/4885GPBAR1 1/4885AGPAT2 484/4885 |
| US-20050090533-A1 | Dual NK1/NK3 receptor antagonists | TACR2, TAC3, TACR1 | ABL1 996/4885GPBAR1 313/4885AGPAT2 3471/4885 |
| US-20110178055-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | TACR2, TAC3, TACR1 | ABL1 996/4885GPBAR1 313/4885AGPAT2 3471/4885 |
| US-20150152058-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | GPBAR1, ADRA1B, GPR119 | ABL1 1707/4885GPBAR1 1/4885AGPAT2 484/4885 |
| US-20090137806-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | TACR2, TAC3, TACR1 | ABL1 996/4885GPBAR1 313/4885AGPAT2 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.